Savage Brian 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2026

Form 4

Period: 2026-03-03

Interim Chief Legal Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-03+3,461→ 4,200 total
Sale
Ordinary Shares
[F1][F3][F4]
2026-03-03$32.36/sh−1,274$41,227→ 2,926 total
Exercise/Conversion
Restricted Share Units
[F2][F5][F1]
2026-03-03−3,461→ 3,461 total
→ Ordinary Shares (3,461 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 3,461 vesting on March 3, 2027.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage|2026-03-05

Documents

1 file